

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3481699

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the NAME OF THE ASSIGNEE previously recorded on Reel 036176 Frame 0794. Assignor(s) hereby confirms the ASSIGNMENT OF ENTIRE INTEREST.
CONVEYING PARTY DATA	
Name	Execution Date
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO S.L.	03/18/2015
RECEIVING PARTY DATA	
Name:	MMV MEDICINES FOR MALARIA VENTURE
Street Address:	INTERNATIONAL CENTER COINTRIN (ICC) BUILDING
Internal Address:	ROUTE DE PRE-BOIS 20
City:	COINTRIN GENEVE
State/Country:	SWITZERLAND
Postal Code:	1216
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13499031
CORRESPONDENCE DATA	
Fax Number:	(352)372-5800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3523758100
Email:	fce@slepatents.com
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	R.C.146
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.
SIGNATURE:	/FRANK C. EISENSCHENK/
DATE SIGNED:	08/13/2015
Total Attachments: 4	
source=2FN4178#page1.tif	
source=2FN4178#page2.tif	
source=2FN4178#page3.tif	

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3453626

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO S.L.	03/18/2015
RECEIVING PARTY DATA	
Name:	MEDICINES FOR MALARIA VENTURE
Street Address:	INTERNATIONAL CENTER COINTRIN (ICC) BUILDING
Internal Address:	ROUTE DE PRE-BOIS 20
City:	COINTRIN GENEVE
State/Country:	SWITZERLAND
Postal Code:	1216
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13499031
CORRESPONDENCE DATA	
Fax Number:	(352)372-5800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3523758100
Email:	fce@slepatents.com
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	R.C.146
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.
SIGNATURE:	/FRANK C. EISENSCHENK/
DATE SIGNED:	07/24/2015
Total Attachments: 3	
source=2FH8493#page1.tif	
source=2FH8493#page2.tif	
source=2FH8493#page3.tif	

ASSIGNMENT AGREEMENT

This Assignment Agreement is made on 5 March 2015 by and between:

GLAXOSMITHKLINE INVESTIGACION Y DESAROLLO S.L., a Spanish limited liability corporation duly organised and validly existing under the laws of Spain with its principal business offices situated at Santiago Grisolia 4, 28760 Tres Cantos, Spain ("GSK"); and

MMV MEDICINES FOR MALARIA VENTURE ("MMV"), a not-for-profit Swiss foundation with its office at the International Center Cointrin (ICC) Building, Route de Pré-Bois 20, 1216 Cointrin Genève, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, GSK does hereby sell, assign and transfer to MMV (hereinafter referred to as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled:
ANTI-MALARIAL AGENTS THAT ARE INHIBITORS OF DIHYDROOROTAE DEHYDROGENASE

PCT Application Number: PCT/US2010/050532

Filing date: 28.09.2010

Publication date: 07.04.2011

Priority Date: 29.09.2009

Priority Number: US/61/246,863

Inventors: Pradipsinh RATHOD, David FLOYD, Jeremy BURROWS, Alka MARWAHA, Ramesh GUJJAR, Jose COTTERON-LOPEZ, Margaret PHILLIPS, Susan CHARMAN and David MATTHEWS

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other

international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by GSK if this sale, assignment and transfer had not been made; and

(9) all data relevant to the invention(s) described in the application referred to in paragraph 1.

GSK hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be

deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of New York. If a dispute arises between the parties concerning any right or duty under this Agreement, then the parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute amicably, then the dispute shall be referred to arbitration under the WIPO Arbitration Rules. The seat of the arbitration shall be New York and the language English.

This Assignment is effective as from the earliest priority date as stated above.

GSK

Executed this 18 day of MARCH, 2015.

N C

Name: N. CAMMACK

Position: HEAD, DDW

MMV MEDICINES FOR MALARIA VENTURE

Executed this 5 day of March, 2015.

W

Name: Sylvie Fonteilles-Drabek
Position: Executive Vice President
Head of Legal

A Buscaglia

Name: Andrea Buscaglia
Position: Chief Financial Officer

Position: DDW